Initial combination aliskiren + amlodipine versus sequential add-on therapy in essential hypertension

Phase 3, randomised, double-blind trial of aliskiren, amlodipine and hydrochlorothiazide in essential hypertension (3 arms), sponsored by Novartis. Primary endpoints: Overall mean change from baseline in mean sitting systolic blood pressure over Weeks 8, 16, and 24 and Change from baseline in mean sitting systolic blood pressure at Week 24. Started Oct 2008; status: completed.